Granules India Delivers Strong Q1 FY27 with 22% Revenue Growth and 60% PAT Increase

What Happened ?

key details

Financial Performance:

• Revenue increased 22% YoY to ₹1,476.8 crore.
• EBITDA grew 37% YoY to ₹338.9 crore.
• EBITDA Margin expanded to 22.9%.
• PAT increased 60% YoY to ₹180 crore.
• Gross Margin improved to 65.6%.
• Cash Flow from Operations nearly reached ₹387.4 crore.
• ROCE improved to 18.0%, reflecting better capital efficiency.

Note:

• While quarterly EBITDA and PAT moderated slightly compared to Q4 FY26, the company maintained significantly stronger year-on-year profitability through better product mix and operating leverage. 

Portfolio Transformation:

• Complex Generics now account for 50% of the Finished Dosage portfolio, compared with 39% in Q1 FY26.
• The shift towards higher-value Complex Generics supported gross margin expansion and improved earnings quality.
• Finished Dosages remained the largest revenue contributor at 74% of total sales.
• Portfolio transformation continues to focus on differentiated, higher-margin products. 

Revenue Mix:

• Business Segments
  • Finished Dosages (FD): 74% of revenue (+22% YoY)
  • API: 13% (+19% YoY)
  • PFI: 9% (+9% YoY)
  • Peptides CDMO: 4% (+106% YoY)

• Geographic Mix
  • North America: 72% of revenue (+13% YoY)
  • Europe: 16% (+51% YoY)
  • Rest of World: 12% (+56% YoY)

Note:

• Growth in Europe and Rest of World continued to diversify the company’s revenue base while maximizing returns on R&D investments. 

Research & Development:

• R&D expenditure increased to ₹88 crore, representing 6.0% of sales.
• Filed 5 Finished Dosage products during the quarter.
• Filed 4 API products.
• Continued investment in Complex Generics, digitalization and differentiated product development to strengthen future growth.

Regulatory & Product Pipeline:

• Secured its second Sole First-to-File opportunity for Sodium Oxybate ER.
• The product targets an estimated branded market opportunity of US$267 million.
• 25 ANDAs remain under regulatory review, targeting a combined branded and generic market opportunity of approximately US$40 billion.
• The GPI manufacturing facility received a Voluntary Action Indicated (VAI) classification along with the FDA Establishment Inspection Report (EIR) following the April 2026 inspection. 

Capital Allocation & Balance Sheet:

• Net Debt reduced to ₹101.2 crore.
• Net Debt/EBITDA improved sharply to 0.07x from 0.34x in FY26.
• Net Working Capital to Sales improved to 29%.
• Capex moderated during the quarter following completion of the Genome Valley investment.
• Future investments will focus on digitalization and modular expansion projects at existing facilities. 

Business Strategy:

• Strengthening regulatory and quality excellence.
• Expanding Complex and Differentiated Generics portfolio.
• Geographic and customer diversification.
• Scaling new growth engines.
• Continued investments in R&D, sustainability, digitalization, operational excellence and talent development. 

Risk Analysis

Summary:

• Granules India continues to strengthen its long-term competitive position through higher-value products, disciplined capital allocation and sustained R&D investment. However, external cost pressures, regulatory requirements and successful commercialization of its pipeline remain key execution factors.

Key Risks:

• Management expects supply chain volatility and input cost pressures to continue over the next few quarters.
• Continued investment in Complex Generics may temporarily impact margins before commercialization.
• North America remains the largest revenue contributor, exposing the company to pricing and regulatory risks.
• Future growth depends on successful approvals and commercialization of pending ANDAs.
• Peptides CDMO reported an EBITDA loss during the quarter as projects remain in the ramp-up phase. 

Worst Case:

• Delays in regulatory approvals, prolonged supply chain disruptions or slower commercialization of Complex Generic products could moderate future earnings growth despite the company’s improving financial position.

Risk Level: Medium

Company Commentary

• Chairman & Managing Director Dr. Krishna Prasad Chigurupati said the strategic initiatives undertaken during FY26 are translating into stronger execution, greater resilience and improved strategic clarity.
• Management remains focused on regulatory and quality excellence, portfolio transformation, customer diversification and scaling new growth platforms.
• The company will continue investing in Complex Generics, digitalization, sustainability, operational excellence and talent to support long-term value creation.
• Despite near-term cost pressures and supply chain volatility, management remains confident of delivering sustainable long-term growth with a stronger and more balanced business portfolio.